PLUR - pluri-biotech.com Debt to Book Capitalization Ratio

Graphic logo of Pluri (PLUR)

Premium pricing for placental therapy is driving stock growth, as evidenced by the financial leverage ratio based on book capitalization. However, Middle Eastern conflicts are undermining stability, and the environmental profile is constrained by bio-waste disposal. The current value of 0.00 represents the debt load indicator, demonstrating the balance between the financial independence of Pluri Inc. (PLUR) and the pace of its business expansion.

PLUR (Pluri) Debt to Book Value history from 04/28/2023 to 10/27/2026
Core merchandise of Pluri

This ratio determines the proportion of financial liabilities to equity, measuring the company's actual debt load. An increase in this value signals an overheated financing structure and heightened default risks. By analyzing the current relationship between debt and balance sheet capital, an investor assesses the sustainability of business scaling. For Pluri Inc. (PLUR), this is critical when maintaining energy-dependent bioreactors in Israel. Monitoring this metric confirms the company's ability to support costly cell therapy infrastructure.

Competitors of Pluri Inc. (PLUR)

Debts to Book Capitalization ASND (Ascendis Pharma A/S)|madrigalpharma.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Corcept Therapeutics Incorporated (CORT)|RYTM: Debt to Net Assets Ratio|AKRO (Akero Therapeutics Inc) - Debt to Book Capitalization Ratio|Metsera Therapeutics (MTSR) - Debt to Book Value|MLTX (MoonLake Immunotherapeutics) - Debts to Book Capitalization|Debts to Book Capitalization crinetics.com (CRNX)|NewAmsterdam Pharma Company N.V. (NAMS) - Debt to Book Value|Debt to Net Assets Ratio SLNO (Soleno Therapeutics Inc)|Amicus Pharma - Debt to Book Capitalization Ratio|Debt to Book Value 89bio Pharma ETNB|AGIO (Agios Pharmaceuticals) - Debts to Book Capitalization|structuretx.com (GPCR) - Debts to Book Value|MDXG - Debt to Book Value|Rezolute Inc (RZLT) - Debt to Book Capital|LXRX (Lexicon Pharma) - Debts to Book Capitalization|Debts to Book Capitalization MBX Corp|Debts to Book Capitalization Altimmune, Inc. (ALT)|Debt to Book Capitalization Ratio AARD (aardvarktherapeutics.com)|SGMT: Debt to Book Capitalization Ratio|BioAge Labs - Debts to Book Value|BMEA - Debt to Book Capitalization Ratio|QNCX - Debt to Book Capitalization Ratio|Fractyl Health, Inc. - Debts to Book Capitalization|VTVT (vTv Therapeutics) - Debts to Net Assets|ATPC: Debt to Book Capitalization Ratio|Debts to Net Assets SYBX|Debt to Book Capitalization Ratio LPCN (Lipocine Corp)|Debt to Book Value MTNB (matinasbiopharma.com)|Spruce Biosciences, Inc. (SPRB) - Debt to Book Capitalization Ratio|galecto.com - Debts to Book Capitalization Ratio|CTCX - Debt to Book Capitalization Ratio|Lumos Pharma Inc (LUMO) - Debt to Book Capitalization Ratio|ONVO: Debt to Book Value|RDUS (Radius Pharmaceuticals) - Debts to Book Capitalization